Literature DB >> 6276701

Comparative activity of N-formimidoyl thienamycin with third generation cephalosporins and ureido penicillins against multiple resistant Serratia marcescens.

M A Miller, J L LeFrock, M J Vercler.   

Abstract

Twenty multiple resistant clinical isolates were tested with N-formimidoyl thienamycin, moxalactam, cefotaxime, cefoperazone, and the three ureidopenicillins: azlocillin, mezlocillin, and piperacillin. A concentration of less than 0.97 microgram/ml inhibited 100% of organisms for N-f-thienamycin and cefotaxime, 90% for moxalactam, and 60% for cefoperazone. An increase in inoculum from 10(3) to 10(6) cells reduced activity fourfold for 95% of isolates with cefoperazone, 70% with N-formimidoyl thienamycin, 65% for cefotaxime, but only 15% for moxalactam. For ureidopenicillins, 85% of strains tested had MIC's less than or equal to 15.6 micrograms/ml. An inoculum effect was observed in only 35-50%. At 10(3), the cidal concentration was the same or twofold greater than the inhibitory level for N-f-thienamycin and cephalosporins in 70% of strains tested and 65% for penicillins. With 10(6), the 70% value remained for N-f-thienamycin but was reduced to 45% for cefotaxime and 25% for moxalactam; 85% demonstrated greater than eightfold differences with cefoperazone. Single step high-level resistance was observed to moxalactam (20%). Carbenicillin resistant strains were cross-resistant to the ureidopenicillins. N-f-thienamycin and cefotaxime appeared comparable, although important differences between morphological alteration and metabolism may influence their therapeutic effectiveness.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6276701     DOI: 10.1111/j.1348-0421.1981.tb00120.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  3 in total

1.  The effect of N-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative Gram-negative rods, Aeromonas, Plesiomonas and Enterobacter agglomerans.

Authors:  A von Graevenitz; C Bucher
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

Review 2.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

3.  Using human genetics to understand the disease impacts of testosterone in men and women.

Authors:  Katherine S Ruth; Felix R Day; Jessica Tyrrell; Deborah J Thompson; Anna Murray; Ken K Ong; Timothy M Frayling; John R B Perry; Andrew R Wood; Anubha Mahajan; Robin N Beaumont; Laura Wittemans; Susan Martin; Alexander S Busch; A Mesut Erzurumluoglu; Benjamin Hollis; Tracy A O'Mara; Mark I McCarthy; Claudia Langenberg; Douglas F Easton; Nicholas J Wareham; Stephen Burgess
Journal:  Nat Med       Date:  2020-02-10       Impact factor: 53.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.